Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model

Li,Zhengguang; Li,Xingyi; Cao,Zhixing; Xu,Youzhi; Lin,Hongjun; Zhao,Yinglan; Wei,Yuquan; Qian,Zhiyong

doi:10.3892/or.2012.1635

Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model

Authors:
- Zhengguang Li
- Xingyi Li
- Zhixing Cao
- Youzhi Xu
- Hongjun Lin
- Yinglan Zhao
- Yuquan Wei
- Zhiyong Qian
View Affiliations

Affiliations: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, #1 Keyuan Road 4, Gaopeng Street, High Technological Development Zone, Chengdu 610041, P.R. China
Published online on: January 12, 2012 https://doi.org/10.3892/or.2012.1635
Pages: 1035-1040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Camptothecin (CPT) exhibits very strong antitumor effects by inhibiting the activity of DNA topoisomerase I, but its application is greatly limited due to its low solubility and the instability of the active lactone form. To overcome these shortcomings, in the present study, we prepared novel camptothecin nanocolloids based on N,N,N-trimethyl chitosan (CPT-TMC) to efficiently and safely administer CPT systemically. Herein, we investigated the antitumor activity of CPT-TMC against a murine Balb/c myeloma model. Our results showed that CPT-TMC more effectively inhibited tumor growth and prolonged survival time than CPT in vivo, but no statistical difference was observed in vitro between CPT-TMC and CPT. These findings suggest that N,N,N-trimethyl chitosan could increase the stability and the antitumor effect of CPT and CPT-TMC is a potential approach for the effective treatment of multiple myeloma.

View Figures

View References

1	Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
2	Rajkumar SV and Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 80:1371–1382. 2005. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
4	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
5	Munshi NC: Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008:2972008. View Article : Google Scholar : PubMed/NCBI
6	Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 88:3888–3890. 1966. View Article : Google Scholar
7	Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260:14873–14878. 1985.PubMed/NCBI
8	Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res. 54:1431–1439. 1994.PubMed/NCBI
9	Takimoto CH, Wright J and Arbuck SG: Clinical applications of the camptothecins. Biochim Biophys Acta. 1400:107–119. 1998. View Article : Google Scholar : PubMed/NCBI
10	Topcu Z: DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther. 26:405–416. 2001. View Article : Google Scholar : PubMed/NCBI
11	Bredholt T, Dimba EA, Hagland HR, et al: Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol Cancer. 8:1012009.PubMed/NCBI
12	Garcia-Carbonero R and Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 8:641–661. 2002.PubMed/NCBI
13	Hatefi A and Amsden B: Camptothecin delivery methods. Pharm Res. 19:1389–1399. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kehrer DF, Soepenberg O, Loos WJ, Verweij J and Sparreboom A: Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs. 12:89–105. 2001. View Article : Google Scholar : PubMed/NCBI
15	Bodley AL, Wani MC, Wall ME and Shapiro TA: Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol. 50:937–942. 1995. View Article : Google Scholar : PubMed/NCBI
16	Haluska P, Rubin E and Verschraegen CF: Topoisomerase-I inhibitors in gynecologic tumors. Hematol Oncol Clin North Am. 13:43–61. vii–viii. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kawano K, Watanabe M, Yamamoto T, et al: Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release. 112:329–332. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sun FX, Tohgo A, Bouvet M, et al: Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 63:80–85. 2003.PubMed/NCBI
19	Zu YG, Li QY, Fu YJ and Wang W: Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg Med Chem Lett. 14:4023–4026. 2004. View Article : Google Scholar : PubMed/NCBI
20	van Hattum AH, Pinedo HM, Schluper HM, Erkelens CA, Tohgo A and Boven E: The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol. 64:1267–1277. 2002.PubMed/NCBI
21	Akimoto K, Kawai A and Ohya K: Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous aolution. Chem Pharm Bulletin. 42:2135–2138. 1994. View Article : Google Scholar
22	Hanson BA, Schowen RL and Stella VJ: A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm Res. 20:1031–1038. 2003. View Article : Google Scholar : PubMed/NCBI
23	Tanizawa A, Fujimori A, Fujimori Y and Pommier Y: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 86:836–842. 1994. View Article : Google Scholar : PubMed/NCBI
24	Burke TG, Staubus AE, Mishra AK and Malak H: Liposomal stabilization of camptothecin’s lactone ring. J Am Chem Soc. 114:8318–8319. 1992.
25	Cortesi R, Esposito E, Maietti A, Menegatti E and Nastruzzi C: Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int J Pharm. 159:95–103. 1997. View Article : Google Scholar
26	Watanabe M, Kawano K, Yokoyama M, Opanasopit P, Okano T and Maitani Y: Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm. 308:183–189. 2006. View Article : Google Scholar : PubMed/NCBI
27	Shenderova A, Burke TG and Schwendeman SP: The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res. 16:241–248. 1999.PubMed/NCBI
28	Tong W, Wang L and D’Souza MJ: Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm. 29:745–756. 2003.PubMed/NCBI
29	Chandy T and Sharma CP: Chitosan-as a biomaterial. Biomater Artif Cells Artif Organs. 18:1–24. 1990.
30	Kotzé AF, Lueßen HL, de Boer AG, Verhoef JC and Junginger HE: Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci. 7:145–151. 1998.PubMed/NCBI
31	Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC and Junginger HE: N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res. 14:1197–1202. 1997.
32	Jintapattanakit A, Mao S, Kissel T and Junyaprasert VB: Physicochemical properties and biocompatibility of N-trimethyl chitosan: effect of quaternization and dimethylation. Eur J Pharm Biopharm. 70:563–571. 2008.PubMed/NCBI
33	Peng X and Zhang L: Surface fabrication of hollow microspheres from N-methylated chitosan cross-linked with gultaraldehyde. Langmuir. 21:1091–1095. 2005. View Article : Google Scholar : PubMed/NCBI
34	Peng X, Zhang L and Kennedy JF: Release behavior of microspheres from cross-linked N-methylated chitosan encapsulated ofloxacin. Carbohydr Polym. 65:288–295. 2006. View Article : Google Scholar
35	Zhilei L, Steenekamp JH and Hamman JH: Cross-linked cationic polymer microparticles: effect of N-trimethyl chitosan chloride on the release and permeation of ibuprofen. Drug Dev Ind Pharm. 31:311–317. 2005. View Article : Google Scholar : PubMed/NCBI
36	Li X, Kong X, Zhang J, et al: A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids. J Pharm Sci. 100:232–241. 2011. View Article : Google Scholar : PubMed/NCBI
37	Yuan ZP, Chen LJ, Fan LY, et al: Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res. 12:3193–3199. 2006. View Article : Google Scholar : PubMed/NCBI
38	Muther RS and Bennett WM: Effects of dimethyl sulfoxide on renal function in man. JAMA. 244:2081–2083. 1980. View Article : Google Scholar : PubMed/NCBI
39	Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:3186–3192. 1993.PubMed/NCBI
40	Rajkumar SV: Multiple myeloma. Curr Probl Cancer. 33:7–64. 2009. View Article : Google Scholar
41	Sirohi B and Powles R: Multiple myeloma. Lancet. 363:875–887. 2004. View Article : Google Scholar : PubMed/NCBI
42	Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2:927–937. 2002. View Article : Google Scholar : PubMed/NCBI
43	Donato ML, Aleman A, Champlin RE, et al: High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 45:755–759. 2004. View Article : Google Scholar : PubMed/NCBI
44	Kraut EH, Crowley JJ, Wade JL, et al: Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol. 16:589–592. 1998.PubMed/NCBI
45	Kraut EH, Young D, Farag S, James AG and Solove RJ: Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leuk Res. 29:1233–1234. 2005. View Article : Google Scholar : PubMed/NCBI
46	Watanabe M, Kawano K, Toma K, Hattori Y and Maitani Y: In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release. 127:231–238. 2008. View Article : Google Scholar : PubMed/NCBI
47	Rinaudo M: Chitin and chitosan: properties and applications. Prog Polym Sci. 31:603–632. 2006. View Article : Google Scholar
48	Cardile V, Frasca G, Rizza L, et al: Improved adhesion to mucosal cells of water-soluble chitosan tetraalkylammonium salts. Int J Pharm. 362:88–92. 2008. View Article : Google Scholar : PubMed/NCBI
49	Snyman D, Hamman JH and Kotze AF: Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev Ind Pharm. 29:61–69. 2003. View Article : Google Scholar : PubMed/NCBI
50	Mourya VK and Inamdar NN: Trimethyl chitosan and its applications in drug delivery. J Mater Sci Mater Med. 20:1057–1079. 2009. View Article : Google Scholar : PubMed/NCBI